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Abstract: The mechanism of FGF23 action in calcium/phosphorus metabolism of patients with chronic kidney disease (CKD) was 
studied using a mathematical model and clinical data in a public domain. We have previously built a physiological model that describes 
interactions of PTH, calcitriol, and FGF23 in mineral metabolism encompassing organs such as bone, intestine, kidney, and para-
thyroid glands. Since an elevated FGF23 level in serum is a characteristic symptom of CKD patients, we evaluate herein potential 
metabolic alterations in response to administration of a neutralizing antibody against FGF23. Using the parameters identified from 
available  clinical data, we observed that a transient decrease in the FGF23 level elevated the serum concentrations of PTH,  calcitriol, 
and phosphorus. The model also predicted that the administration reduced a urinary output of phosphorous. This model-based pre-
diction indicated that the therapeutic reduction of FGF23 by the neutralizing antibody did not reduce phosphorus burden of CKD 
patients and decreased the urinary phosphorous excretion. Thus, the high FGF23 level in CKD patients was predicted to be a failure of 
 FGF23-mediated  phosphorous excretion. The results herein indicate that it is necessary to understand the mechanism in CKD in which 
the level of FGF23 is elevated without effectively regulating phosphorus.
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Introduction
Fibroblast growth factor-23 (FGF23) has recently 
been demonstrated to represent a critical  circulating 
hormone involved in phosphorus metabolism.1 
Since phosphorus metabolism is tightly linked to cal-
cium homeostasis in organs such as bone and kidney, 
signaling interactions should exist between FGF23 
and regulators of calcium metabolism  including 
 parathyroid hormone (PTH) and the active form of 
vitamin D (1,25-dihydroxyvitamin D; calcitriol).2 
Thus, a traditional, physiological model with PTH and 
calcitriol needs to be rebuilt in accordance with the 
emerging role of FGF23 and its interacting  molecules. 
To understand probable interactions among FGF23, 
PTH and calcitriol, we previously developed a mini-
mum physiological model of calcium/phosphorus 
metabolism and investigated potential influences of 
FGF23 on the observable state variables such as the 
serum concentrations of PTH, calcitriol, calcium (Ca), 
and phosphorous (P), as well as the urinary excretion 
of Ca and P.3 In this study, we extended the model and 
evaluated the mechanism of FGF23-mediated regula-
tion in chronic kidney diseases (CKD).
The FGF23 gene was identified by its mutations asso-
ciated with autosomal dominant hypophosphatemic 
rickets (ADHR), which is an inherited phosphate 
wasting disorder.4 Thereafter, a variety of disorders 
resulting from gain or loss of FGF23  bioactivity have 
been reported.5 These disorders, which are caused 
by mutations in the genes that directly or indirectly 
interact with FGF23, include hyperphosphatemic 
familial tumoral calcinosis (HFTC), hereditary hypo-
phosphatemic rickets with hypercalciuria (HHRH), 
autosomal recessive  hypophosphatemic rickets 
(ARHR), and X-linked dominant hypophosphatemic 
rickets (XLH, HYP). CKD patients who need dialy-
sis have very high levels of FGF23 in serum that are 
linked with increased rates of death.6 Little is known 
about functional significance of the elevated FGF123 
level in CKD.
In this study, we examined whether the therapeu-
tic reduction of FGF23 by the neutralizing antibody 
would modulate phosphorus balance of CKD patients. 
To this end, we first evaluated the levels of physiolog-
ical variables such as the levels of PTH, calcitriol, 
FGF23, Ca, and P in serum as well as urinary outputs 
of Ca and P using clinical data. Since a glomerular 
filtration rate (GFR) is a good indicator of severity 
of CKD, data were processed as a function of GFR. 
We then employed the previously developed mathe-
matical model for mineral metabolism, and conducted 
numerical simulations in response to the modulation 
of FGF23 by neutralizing antibody.
Materials and Methods
clinical data
Clinical data such as the serum concentrations of 
FGF23, PTH, calcitriol, Ca, and P, as well as  urinary 
outputs of Ca and P were obtained from published 
articles as previously described.7 We analyzed 
data in the following literature: data for healthy 
individuals;8,9 data for CKD;10–15 data for Tumor 
Induced Osteomalacia;8 data for Fibrous Dysplasia;16 
and data for XLH.17 In brief, the individual points 
in literature were retrieved with the DIGITIZEIT 
software. To establish correlations between two of 
the chosen physiological variables, one variable was 
treated as an independent (driving) variable, sorted 
in an ascending order and then smoothed out with a 
sliding average of 3–5 consecutive values.18,19 Values 
larger than 1.5 times the interquartile range between 
1st and 3rd quartiles (e.g. 500 pg/ml or larger for 
PTH) were considered outliers. The smoothed data 
sets were then partitioned into frequency classes 
with the help of the SPSS (version 16.0) software. 
For each class, means and their standard errors were 
computed and plotted.
estimation of the relationship  
of the FGF23 level to other  
physiological variables
The FGF23 concentrations, reported in literature, con-
siderably varied among available datasets,  presumably 
caused by differential baseline levels or sensitiv-
ity variations among individual assays. To predict a 
quantitative relationship among the FGF23 level and 
other physiological variables, the reported FGF23 
level was linearly modified:
 [FGF23]AB = {[FGF23]-A}/B (1)
in which [FGF23] = reported FGF23 level, 
[FGF23]AB = linearly modified FGF23 level, and A 
and B = two correction factors. Note that these cor-
rection factors are constant and they were chosen 
independently for each of the physiological variables 
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such as the serum level of PTH and the urinary output 
of P. The “+” and “-” values of the factor B indicate 
positive and  negative correlations to the FGF23 level, 
respectively. We applied the described modification 
in analyzing clinical data since the observed FGF23 
variation was larger than others. Without this proce-
dure, it was  difficult to estimate a quantitative rela-
tionship of its concentrations to other variables.
Mathematical model and prediction  
of effects of FGF23 antibody
We previously developed a pair of metabolism 
 models of calcium and phosphorus with and with-
out  including the predicted action of FGF23.3,20 In 
this study we considered an additional state variable, 
GFRf, as a multiplicative term pertaining to the cal-
cium and phosphorus renal thresholds and the kidney 
production of calcitriol:
 GFRf = (GFR/GFR0)k (2)
in which GFR0 and GFR = glomerular filtration rates 
in the control state and at any given degree of renal 
failure, respectively, and a factor k (.0) was chosen 
so as to fit the clinical data as described previously.7
To predict the effects of intravenous administration 
of a neutralizing antibody against FGF23, we numeri-
cally examined 5 different dosages for i.v.  administration 
at 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg (dosage  levels 
1–5). These dosages corresponded to a clinical trial 
study being proposed for a  dose-escalation study of 
KRN23 (Kyowa Hakko Kirin Pharma Inc.). A pri-
mary outcome measure of this Phase I  clinical trial is a 
change in a serum phosphate level, and a single dose by 
 intravenous or subcutaneous administration is planned. 
The initial target is X-linked hypophosphatemia but 
no clinical data regarding efficacy and side effects are 
available. To simulate a probable injection procedure, 
we assumed a form of a single, smoothed-out pulse. The 
rise in the antibody concentration was modeled using a 
Gaussian type diffusion profile with a period dependent 
on the distribution volume and cardiac output.
Results
Glomerular filtration rate (GFR)  
as an indicator in cKD patients
Since GFR serves as one of the best  indicators 
of  kidney function and a stage of kidney  disease, 
we plotted physiological variables of CKD 
patients as a  function of GFR in ml/min/1.73 m2. 
Figure 1  illustrated the levels of PTH (pg/ml), 
calcitriol (pg/ml), Ca (mg/dl), and P (mg/dl) in serum 
as well as urinary outputs of Ca and P expressed as a 
fraction of the glomerular loads. The numbers in the 
brackets in Figure 1 were the numbers of patients. 
The average and SEM  values were obtained in each 
of the sampling bins. As GFR was normal above 
90, the levels of PTH and P in serum as well as the 
fractions of urinary Ca and P outputs were lowered. 
On the contrary, the level of calcitriol in serum was 
higher as GFR increased.
estimation of FGF23 levels in serum  
in cKD patients
The relationships of the linearly modified FGF23 
concentration in serum, [FGF23]AB, to the selected 
physiological variables in CKD patients were 
 illustrated in Figure 2. First, a strong correlation was 
observed between loge(GFR) and a negative form of 
loge[FGF23]AB, indicating that the FGF23 level was 
sharply elevated in CKD patients with  reduction 
in GFR. Second, an increase in [FGF23]AB was 
 correlated to the levels of PTH, calcitriol, P in serum, 
and the renal threshold for P. Note that a positive 
correlation (i.e. B . 0) was observed for the levels 
of PTH and P in serum, while a negative correlation 
(i.e. B , 0) for the serum level of calcitriol and the 
renal threshold for P. Note that a majority of data 
points had the PTH level above 50 pg/ml, indicat-
ing a poor balance of mineral metabolism in CKD 
patients.
Linkage of FGF23 and P levels in serum
Since a primary known role of FGF23 is regulation of 
the serum level of P, we evaluated the dependence of 
P on the modified FGF23 level in healthy  populations, 
and patients with Tumor Induced Osteomalacia, 
Fibrous Dysplasia, and XLH (Fig. 3). In all groups, 
a positive correction was observed between the level 
of P and the modified level of FGF23 in serum. 
Note that CKD data in Figure 2D showed the elevated 
P level up to 6 mg/dl, while the higher bound of the 
P level was ∼2 mg/dl (Tumor Induced  Osteomalacia), 
3.5 ∼4 mg/dl (Fibrous Dysplasia and XLH), and 
4.5 mg/dl (healthy populations).
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Predicted effects of the antibody 
specific to FGF23
Although the observed increase of FGF23 in CKD 
is apparently a physiological response to hyperphos-
phatemia, the use of FGF23 antibody is suggested 
for transplanted hypophosphatemic patients of CKD 
with a high level of FGF23.21 In response to intra-
venous administration of the antibody  specific to 
FGF23, we evaluated the predicted changes in the 
serum levels of PTH, calcitriol, and P as well as a 
normalized urinary output of P. The prediction is 
also useful for a patient with a primary increase in 
FGF23 secretion such as in XLH. The initial condi-
tions were: FGF23 = 170 pg/ml, PTH = 20 pg/ml, cal-
citriol = 8 pg/ml, and P = 1.92 mg/dl. Five different 
dosages were employed as indicated in the Materials 
and Methods section (dosage levels 1–5).
The results showed that antibody injection 
 immediately reduced the level of FGF23 in a dos-
age dependent manner, but the level was restored to 
its original concentration in 1 hr except for the case 
with the highest antibody concentration (Fig. 4). In 
concert with this  alteration in the FGF23 concentra-
tion, the  levels of PTH, calcitriol, and P in serum 
were elevated.  Interestingly, the transient responses 
presented their own characteristics. The PTH level 
was elevated for 1 hr and then stabilized at the level 
below the  original concentration. The level of cal-
citriol had a longer response time than that of PTH, 
and it took 10–14 hrs to reach to the original level. 
The serum concentration of P exhibited an overshoot 
for the injection with the highest antibody concentra-
tion. In response to the lowered level of FGF23, the 
urinary output of P, expressed as a fraction of the P 
glomerular load, was transiently decreased for 1 hr. 
No increase of the urinary output of P was observed.
Discussion
Analysis of clinical data from patients with CKD 
clearly showed that GFR was a good overall indica-
tor of examining physiological state variables such as 
the serum concentrations of PTH, calcitriol, FGF23, 
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Ca, and P as well as urinary outputs of Ca and P. In 
a severe CKD state with GFR , 30 ml/min/1.73 m2, 
the serum levels of PTH and P were significantly 
 elevated while the levels of calcitriol and Ca were 
lower than healthy individuals. These clinical data also 
revealed a negative correlation between loge(GFR) 
and loge(FGF23), indicating that CKD patients with 
low GFR presented an exponential increase of the 
FGF23 level in serum. Since CKD patients are hyper-
phosphatemic with a high level of P in serum, dietary 
restriction with low phosphorus is recommended. Fur-
thermore, administrations of sevelamer  carbonate22 
and lanthanum carbonate23 have been clinically exam-
ined to reduce phosphorus burden. However, without 
using a quantitative physiological model it is difficult 
to evaluate the role of FGF23 in CKD.
In this study, model-based evaluations of the role 
of FGF23 in CKD were conducted using  numerical 
simulations in response to neutralizing  antibody 
against FGF23. Antibodies specific to FGF23 were 
originally developed to investigate the effects of 
FGF23  inhibition on the serum levels of P and 
 calcitriol in normal mice as well as Hyp mice.24,25 
In Hyp mice  (hypophosphatemic mice, phenotypi-
cally  similar to XLH), injections of FGF23 antibody 
 ameliorated the rachitic bone phenotypes such as 
impaired  longitudinal elongation, defective miner-
alization, and abnormal cartilage development, sug-
gesting a novel therapeutic potential of the FGF23 
antibodies for XLH. Although the serum level of P 
substantially differs in CKD and XLH, these two 
 metabolic diseases exhibit a high serum level of 
FGF23. However, application of FGF23 antibody 
to CKD in our mathematical model did not result in 
removing  phosphorous burden.
The present results from the computational 
 simulations herein do not support the notion that 
the elevated level of FGF23 in serum in CKD is a 
direct cause of hyperphosphotemia. On the  contrary, 
these simulations indicate that the high FGF23 
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level is not a cause but an outcome of an ineffective 
FGF23-mediated phosphorus removal. Our current 
working hypothesis is, therefore, that an exponential 
increase in the level of FGF23 in CKD is induced by 
the reduction in GFR for restoring normal phospho-
rus homeostasis. Although the increase in FGF23 in 
serum is linked with high rates of death, the results 
from this study suggest that a removal of FGF23 by 
administration of neutralizing antibody to FGF23 is 
not a proper therapeutic strategy for CKD. The exact 
mechanism of FGF23 regulation in CKD is, however, 
not known, and further basic and clinical investiga-
tions are necessary.
There are limitations in the mathematical model, 
since many molecular pathways in mineral metabolism 
are not completely determined. FGF23 is known to 
affect, for instance, multiple forms of sodium-phosphate 
 co-transporters in kidney through interactions with 
Klotho and cognate FGF receptors,26 but the  current 
mathematical model does not include individual molec-
ular components as state variables. Furthermore, a phos-
phorous sensing mechanism, presumably by conducted 
osteocytes in bone, or a molecular communication link 
of intestine to kidney is yet to be clarified.
In summary, we presented computational analysis 
using a multiscale, physiological model and  clinical 
data to understand calcium/phosphorus metabolism. 
The present model in this study extended the previ-
ous ones including the action of FGF23 and GFR as 
an additional state variable and clinical data from 
patients with CKD.3,20 Through further refinements of 
molecular interactions encompassing a multi-organ 
system, we expect that model-based simulations will 
be useful to predict efficacy of potential therapeutic 
strategies prior to clinical trials.
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